econd-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.

Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R.

Cancer Immunol Immunother   2023.11

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.

Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, Sakamoto H, Amino Y, Ariyasu R, Uchibori K, Kitazono S, Seike M, Gemma A, Nishio M.

Invest New Drugs.   2023.6

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med.   62 ( 4 )   589 - 593   2023.2

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).

Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer.   2022.5